Corporate Profile
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.
Stock Quote
Change
Volume
Dec 3, 2023 8:40 AM
Data Provided by Refinitiv. Minimum 15 minutes delayed.